| № п./п. | Название исследования | Год |
|---------|-----------------------|-----|
| 1       | Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines | 2020 |
|         | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248264/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248264/) |     |
| 2       | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine a dose-escalation, open-label, non-randomised, first-in-human trial | 2020 |
|         | [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext) |     |
| 3       | Immunogenicity and safety of a recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial | 2020 |
|         | [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext) |     |
| 4       | A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes | 2020 |
|         | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309451/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309451/) |     |
| 5       | Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption | 2020 |
|         | [https://www.nature.com/articles/s41591-020-0774-y](https://www.nature.com/articles/s41591-020-0774-y) |     |
| 6       | Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses | 2020 |
|         | [https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1](https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1) |     |
| 7       | The fiber knob protein of human adenovirus type 49 mediate highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism | 2020 |
|         | [https://www.biorxiv.org/content/10.1101/2020.07.20.213223v1](https://www.biorxiv.org/content/10.1101/2020.07.20.213223v1) |     |
| 8       | Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice | 2020 |
|         | [https://www.nature.com/articles/s41594-020-0200-y](https://www.nature.com/articles/s41594-020-0200-y) |     |
| 9       | Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein | 2019 |
|         | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/) |     |
| 10      | State-of-the-art human adenovirus vectorology for therapeutic approaches | 2019 |
|         | [https://pubmed.ncbi.nlm.nih.gov/31758807/](https://pubmed.ncbi.nlm.nih.gov/31758807/) |     |
| 11      | Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor | 2019 |
|         | [https://advances.sciencemag.org/content/5/9/eaax3567](https://advances.sciencemag.org/content/5/9/eaax3567) |     |
| 12      | Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs | 2019 |
|         | [https://www.sciencedirect.com/science/article/pii/S0264410X19312307](https://www.sciencedirect.com/science/article/pii/S0264410X19312307) |     |
| 13      | Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates | 2018 |
|         | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/) |     |
| #  | Title                                                                 | Year |
|----|----------------------------------------------------------------------|------|
| 14 | Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge | 2018 |
| 15 | Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys | 2018 |
| 16 | First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector | 2018 |
| 17 | Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus | 2018 |
| 18 | Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 1) | 2017 |
| 19 | Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 2) | 2017 |
| 20 | Векторные вакцины против болезни, вызванной вирусом Эбола | 2017 |
| 21 | Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle | 2017 |
| 22 | Recent advances in genetic modification of adenovirus vectors for cancer treatment | 2017 |
| 23 | Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective | 2016 |
| 24 | Adenoviral vector-based strategies against infectious disease and cancer | 2016 |
| 25 | First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens | 2016 |
| 26 | IMMUNOBIOLOGICAL DRUG AND METHOD FOR USING SAME FOR INDUCING SPECIFIC IMMUNITY AGAINST THE EBOLA VIRUS | 2016 |
| 27 | Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats | 2015 |
| No. | Title                                                                                                                                   | DOI                                                                 | Date   |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|--------|
| 28  | High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial       | https://pubmed.ncbi.nlm.nih.gov/26333337/                           | 2015   |
| 29  | Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy Malaria-Naïve adults         | https://pubmed.ncbi.nlm.nih.gov/26148007/                           | 2015   |
| 30  | Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans | https://pubmed.ncbi.nlm.nih.gov/25165165/                           | 2015   |
| 31  | A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative african adults | https://pubmed.ncbi.nlm.nih.gov/26252526/                           | 2015   |
| 32  | A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141687 | 2015   |
| 33  | Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection | https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003089 | 2014   |
| 34  | First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)                                  | https://pubmed.ncbi.nlm.nih.gov/24719474/                           | 2014   |
| 35  | Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial | https://pubmed.ncbi.nlm.nih.gov/25007091/                           | 2014   |
| 36  | A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity | https://pubmed.ncbi.nlm.nih.gov/24089406/                           | 2013   |
| 37  | Viral vectors for vaccine applications                                                                                               | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710930/               | 2013   |
| 38  | Using Multivalent Adenoviral Vectors for HIV Vaccination                                                                             | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060347 | 2013   |
| 39  | Interleukin-Encoding Adenoviral Vectors as Genetic Adjuvant for Vaccination against Retroviral Infection                              | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082528 | 2013   |
| 40  | Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans, Vaccine | https://pubmed.ncbi.nlm.nih.gov/23357198/                           | 2013   |
| 41  | Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PFCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin | https://pubmed.ncbi.nlm.nih.gov/23357198/                           | 2013   |
| ID | Reference                                                                 | Year |
|----|---------------------------------------------------------------------------|------|
| 42 | A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age | 2013 |
| 43 | First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine | 2013 |
| 44 | DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity | 2013 |
| 45 | Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans | 2013 |
| 46 | Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species | 2012 |
| 47 | Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man | 2012 |
| 48 | Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines | 2012 |
| 49 | Adenovirus 5-vected P.falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults | 2011 |
| 50 | A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) | 2011 |
| 51 | The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert | 2010 |
| 52 | Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Response | 2010 |
| 53 | Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus | 2009 |
| 54 | Advanced Malignant Pleural orPeritoneal Effusion in Patients Treatedwith Recombinant Adenovirus p53Injection plus Cisplatin | 2008 |
| Adenoviruses: Malignant Transformation and Oncology | 2008 |
|-----------------------------------------------|------|
| https://www.sciencedirect.com/science/article/pii/B9780123744104003575 |

| Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-α and antibody responses in mice | 2008 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://www.sciencedirect.com/science/article/pii/S0264410X08004180 |

| A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults, Vaccine | 2008 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/18448211/ |

| Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors | 2007 |
|-----------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/17685831/ |

| Protective immunity against botulism provided by a single dose vaccination with an adenovirus vectored vaccine | 2007 |
|---------------------------------------------------------------------------------------------------------------|------|
| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077857/ |

| Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity | 2006 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/16963747/ |

| Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity | 2005 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/19559110/ |

| Adenoviral vectors: a promising tool for gene therapy | 2005 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/16622281/ |

| Good Manufacturing Practice Production of Adenoviral Vectors for Clinical Trials | 2005 |
|-----------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/15812223/ |

| Gene therapy clinical trials worldwide 1989–2004—an overview | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://onlinelibrary.wiley.com/doi/10.1002/jgm.619 |

| Adenoviruses as Vaccine Vectors | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://www.sciencedirect.com/science/article/pii/S1525001604013425 |

| Safety of Adenoviral Vectors: Results of Clinical Investigations in 445 Cancer Patients Treated with Advexin® (Adenoviral p53) Gene Therapy | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://cyberleninka.org/article/n/1336451 |

| Adenoviral vectors for gene transfer and therapy | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://onlinelibrary.wiley.com/doi/abs/10.1002/jgm.496 |

| Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://jvi.asm.org/content/79/2/771 |

| Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity | 2004 |
|----------------------------------------------------------------------------------------------------------------------------------|------|
| https://pubmed.ncbi.nlm.nih.gov/15128818/ |
| ID | Title                                                                 | Year |
|----|----------------------------------------------------------------------|------|
| 70 | Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission | 2004 |
| 71 | Production of adenovirus vector for gene therapy                      | 2002 |
| 72 | Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response | 2002 |
| 73 | A New Vector System with Inducible E2a Cell Line for Production of Higher Titer and Safer Adenoviral Vectors | 2000 |
| 74 | Human adenovirus type 5 vectors expressing rabies glycoprotein        | 1996 |
| 75 | Adenovirus vectors as recombinant viral vaccines                     | 1995 |
| 76 | Gene therapy using adenoviral vectors                                | 1994 |
| 77 | Adenoviruses as expression vectors and recombinant vaccines          | 1990 |

**Links:**

- [https://www.nature.com/articles/7700765](https://www.nature.com/articles/7700765)
- [https://pubmed.ncbi.nlm.nih.gov/14550017/](https://pubmed.ncbi.nlm.nih.gov/14550017/)
- [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459421/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459421/)
- [https://pubmed.ncbi.nlm.nih.gov/10998335/](https://pubmed.ncbi.nlm.nih.gov/10998335/)
- [https://www.sciencedirect.com/science/article/pii/S0264410X96000126](https://www.sciencedirect.com/science/article/pii/S0264410X96000126)
- [https://www.sciencedirect.com/science/article/pii/0958166994900841](https://www.sciencedirect.com/science/article/pii/0958166994900841)
- [https://pubmed.ncbi.nlm.nih.gov/1366528/](https://pubmed.ncbi.nlm.nih.gov/1366528/)